Merck’s Post

#LabConnect #ClinicalTrials #VaccineTrials The science is clear. Vaccines have had a significant impact on supporting healthier communities around the world. Whether you’re developing one of the hundreds of vaccine candidates for respiratory infections, or are a pioneer in vaccines for less explored infections, #LabConnect is ready to work with you. Learn more and explore how we can partner together to accelerate the development of new vaccines today 👉 https://lnkd.in/e-T3wWJw

The science is clear. Vaccines have had a significant impact on supporting healthier communities around the world. Whether you’re developing one of the hundreds of vaccine candidates for respiratory infections, or are a pioneer in vaccines for less explored infections, LabConnect is ready to work with you. Learn more and explore how we can partner together to accelerate the development of new vaccines today  = > https://lnkd.in/e-T3wWJw #LabConnect #ClinicalTrials #VaccineTrials

This week, Dr. Meghan Pennini, ASPR’s Chief Vaccines and Therapeutics Officer, talked with the Infectious Disease Society of America about actions you can take to protect yourself and your patients from COVID-19, RSV, and flu this fall. Listen to this podcast episode to learn about safe, effective, low-cost treatments for COVID-19; developments in vaccines for COVID, flu, and RSV; protecting children, older adults, and other at-risk individuals; and more. https://lnkd.in/g8nSDSx8

We can learn valuable lessons from the COVID-19 pandemic that can be applied to combating hepatitis B, a preventable liver disease. Prioritizing vaccines over treatment, educating people to humanize the disease, and other strategies can make a significant impact. Let's work together to apply these insights and improve public health outcomes. #COVID19 #HepatitisB #PublicHealth #Vaccines #Education

Respiratory Vaccine Landscape To better understand the intricate landscape of respiratory disease vaccines, Sermo surveyed 198 HCPs in the US using their @RealTime insights platform. From the active role HCPs play in counseling patients to the nuanced prioritization of vaccines in older patients and the barriers faced in recommending specific vaccines, explore the data-driven revelations that shape the landscape of respiratory disease vaccines. Read and Download Here: https://lnkd.in/dbuEhPsX

🧐 Swipe below to see some Myth-Busting Common Misconceptions about #HepatitisB.

I (mostly) work with Streptococcus pneumoniae, also called pneumococcus, the most common bacterial cause of pneumonia. Pneumococcal disease is difficult to prevent, for lots of reasons, but I'll pick a few big ones: 🔷There are over 100 subtypes, or serotypes, of pneumococcus 💯 🔷 Currently licensed vaccines cover up to 20 serotypes 💉 🔷 Vaccines are effective 👍 but expensive 👎 #WorldPneumoniaDay

mRNA vaccines have revolutionized our approach to infectious diseases, showing incredible success with COVID-19. But this is just the beginning! Here's what the future holds For regular updates on healthcare click on: https://lnkd.in/d-QEujDB #mRNAVaccines #FutureOfVaccines #PersonalizedMedicine #TailoredVaccines #VaccineInnovation #BroadSpectrumProtection #EmergingPathogens #CancerVaccines

Why do some people hospitalized with COVID-19 succumb, while others—with apparently similar disease severity at the time of hospitalization—survive? Among older individuals, are there particular immune responses to SARS-CoV-2 virus infection that set the stage for the increased risk of severe COVID-19? These are among the questions addressed in the NIAID-funded Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) study. Two recent publications by IMPACC network investigators provide a detailed picture of the immunologic dynamics of COVID-19 disease in a large cohort of patients who were hospitalized prior to the wide-spread availability of COVID vaccines. Learn more at https://go.nih.gov/8yKlCva

Looking for ways to fight Bovine Respiratory Disease (BRD)? Veer from the herd and experience the benefit of relevant, real-world protection with Bimeda Biologicals’ Myco-Bac® and Pro-Bac™ killed bacterial vaccines powered by the Reveal ATS™ adjuvant and the Stimulator® line of modified live virus (MLV) vaccines. Take a different path. Get better outcomes.